Li Kaixuan, Zong Dongjiang, Sun Jianrong, Chen Danxiang, Ma Minkai, Jia Liqun
Department of Integrated Traditional Chinese and Western Medicine Oncology, China-Japan Friendship Hospital, Beijing, China.
Beijing University of Chinese medicine, Beijing, China.
Front Oncol. 2022 Jun 30;12:830894. doi: 10.3389/fonc.2022.830894. eCollection 2022.
The immunohistochemical definition of estrogen/progesterone receptors dictates endocrine feasibility in the treatment course of breast cancer. Characterized by the deficiency of estrogen receptor α, ERα-negative breast cancers are dissociated from any endocrine regimens in the routine clinical setting, triple-negative breast cancer in particular. However, the stereotype was challenged by triple-negative breast cancers' retained sensitivity and vulnerability to endocrine agents. The interplay of hormone action and the carcinogenic signaling program previously underscored was gradually recognized along with the increasing investigation. In parallel, the overlooked endocrine-responsiveness in ERα-negative breast cancers attracted attention and supplied fresh insight into the therapeutic strategy in an ERα-independent manner. This review elaborates on the genomic and non-genomic steroid hormone actions and endocrine-related signals in triple-negative breast cancers attached to the hormone insensitivity label. We also shed light on the non-canonical mechanism detected in common hormone agents to showcase their pleiotropic effects.
雌激素/孕激素受体的免疫组化定义决定了乳腺癌治疗过程中的内分泌可行性。雌激素受体α（ERα）阴性的乳腺癌以ERα缺乏为特征，在常规临床环境中与任何内分泌治疗方案无关，尤其是三阴性乳腺癌。然而，三阴性乳腺癌对内分泌药物仍具有敏感性和易感性，这一传统观念受到了挑战。随着研究的不断深入，激素作用与先前强调的致癌信号程序之间的相互作用逐渐得到认可。与此同时，ERα阴性乳腺癌中被忽视的内分泌反应性引起了关注，并以不依赖ERα的方式为治疗策略提供了新的见解。本综述阐述了附着在激素不敏感标签上的三阴性乳腺癌中的基因组和非基因组类固醇激素作用以及内分泌相关信号。我们还揭示了常见激素药物中检测到的非经典机制，以展示它们的多效性作用。
